When professional athletes like Cristiano Ronaldo invest in personal hyperbaric chambers for recovery, it signals how deeply HBOT has penetrated sports culture. Yet the clinical evidence supporting such applications has remained fragmented—until now. A comprehensive systematic review published August 10, 2026, in BMC Musculoskeletal Disorders offers the most rigorous assessment to date of HBOT’s efficacy across the full spectrum of musculoskeletal conditions, from delayed-onset muscle soreness to avascular necrosis of the hip.
The German research team from Erlangen and Rostock analyzed 19 clinical studies involving 612 patients, spanning three decades of research from January 1996 to January 2026. Their findings reveal a nuanced picture: HBOT demonstrates consistent benefits for certain bone conditions while showing limited efficacy for the sports recovery applications most commonly marketed to athletes.
Where the Evidence Holds Up
The review’s most robust findings concern avascular necrosis (AVN) of the femoral head and bone marrow edema (BME). For these conditions, HBOT showed consistent improvements across imaging parameters, pain scores, and functional outcomes—particularly when patients received extended treatment protocols of 20 to 80 sessions.
“AVN and BME studies reported consistent improvements in imaging, pain and functional scores, particularly with prolonged protocols,” the authors note, highlighting that these bone conditions responded more favorably than soft-tissue injuries. The mechanism likely relates to HBOT’s capacity to enhance oxygen delivery to ischemic bone tissue, potentially slowing or reversing the necrotic process that characterizes AVN.
This finding aligns with case series and cohort studies dating back to 2015, where patients with early-stage femoral head osteonecrosis demonstrated preserved joint architecture following HBOT protocols. The Erlangen team emphasized that timing appears critical—interventions in earlier disease stages (Ficat stages I and II) showed better outcomes than attempts to salvage advanced collapse.
The Athletic Recovery Gap
Where the systematic review challenges prevailing marketing claims is in the domain of exercise-induced muscle damage (EIMD) and its symptomatic manifestation, delayed-onset muscle soreness (DOMS). Despite HBOT’s popularity among professional sports teams, the randomized controlled trials included in this review showed no significant benefit for post-exercise recovery.
The analysis encompassed multiple RCTs examining HBOT’s effects on inflammatory markers, oxidative stress, and functional recovery following controlled exercise protocols. Harrison’s 2001 study, Webster’s 2002 trial, and more recent work by Gusić in 2024 all converged on similar conclusions: while HBOT demonstrably increases tissue oxygenation, this biochemical effect does not translate into clinically meaningful improvements in muscle recovery timelines.
“Evidence for HBOT’s effects in DOMS/EIMD was limited, with RCTs showing no significant benefit,” the authors conclude—a finding that directly contradicts the wellness industry’s promotion of HBOT as a recovery accelerator for athletes.
Ligaments and Tendons: The Murky Middle
For ligament injuries, the review identified limited evidence suggesting potential benefits, though the methodological quality of available studies constrained definitive conclusions. A 2019 non-randomized study of Japanese rugby players with grade 2 medial collateral ligament injuries showed promising recovery trajectories, but the absence of randomization and blinding limits interpretability.
Tendon oxygenation studies proved particularly inconclusive. While Kubo’s 2012 work demonstrated acute changes in tendon blood flow following HBOT, the clinical significance of these hemodynamic shifts remains uncertain. The review notes that “tendon oxygenation effects were inconclusive”—a candid admission that more rigorous trials are needed.
Safety and Protocol Variability
Across all 19 studies, adverse events proved rare and generally mild—primarily barotrauma affecting the middle ear or sinuses. No serious oxygen toxicity events were reported, suggesting that HBOT maintains its favorable safety profile even when extended to 80 sessions for bone pathologies.
However, protocol variability emerged as a significant limitation. HBOT regimens ranged from a single session to 80 treatments, with durations varying from 60 to 90 minutes at pressures typically between 2.0 and 2.4 atmospheres absolute (ATA). This heterogeneity complicates efforts to establish standardized treatment guidelines and may explain some of the inconsistent findings across studies.
The FDA Perspective: Off-Label Realities
The systematic review’s publication arrives against a backdrop of heightened regulatory scrutiny. The FDA has not cleared HBOT for any musculoskeletal indication except as adjunctive therapy for certain bone infections (osteomyelitis) when refractory to conventional treatment. AVN, BME, sports injuries, and ligament conditions all fall outside FDA-cleared indications—meaning clinical use for these conditions constitutes off-label prescribing.
In its August 2025 safety communication, the FDA reiterated concerns about HBOT device misuse, including fire risks and inappropriate home use. The agency specifically noted that “HBOT has not been cleared or approved to treat musculoskeletal sports injuries”—a position that this systematic review substantiates through rigorous evidence synthesis.
Implications for Clinical Practice
For orthopedic surgeons and sports medicine physicians, the review offers practical guidance: HBOT may warrant consideration as adjunctive therapy for AVN and BME, particularly when surgical options carry significant morbidity or when patients seek to delay joint replacement. The evidence base here, while not derived from large randomized trials, shows sufficient consistency across multiple cohort studies to support informed clinical discussion.
Conversely, the evidence does not support routine HBOT prescription for post-exercise recovery, DOMS, or tendon pathologies. Athletes and teams investing in hyperbaric chambers for these purposes should understand that they are operating outside the boundaries of established clinical evidence—and, in the United States, outside FDA-cleared indications.
Future Research Priorities
The Erlangen team identifies clear priorities for advancing the field: adequately powered RCTs for ligament injuries, standardized outcome measures across tendon studies, and mechanistic research to understand why bone tissue responds more favorably than muscle to hyperbaric oxygenation. The divergence in treatment response between osseous and soft-tissue structures suggests that HBOT’s therapeutic window may be narrower than enthusiast claims suggest—but nonetheless real for carefully selected indications.
As hyperbaric medicine continues its expansion from diving emergencies into elective musculoskeletal care, this systematic review provides a sober calibration of where the science stands. For AVN and BME, HBOT offers genuine therapeutic potential. For athletic recovery marketing, the evidence suggests a different story—one that patients, practitioners, and professional sports franchises would do well to consider before investing in chamber time.
This article is for informational purposes only and does not constitute medical advice. HBOT for musculoskeletal conditions outside FDA-cleared indications is considered off-label use. Patients should consult qualified healthcare providers to discuss risks, benefits, and alternatives.
Sources
- Weinrich L et al. Effects of hyperbaric oxygen therapy on human musculoskeletal pathologies in clinical studies: a systematic review. BMC Musculoskelet Disord. 2026;27(1):661.
- FDA Consumer Updates: Hyperbaric Oxygen Therapy—Get the Facts
- FDA Letter to Health Care Providers: Follow Instructions for Safe Use of HBOT Devices (August 2025)